Pharmacogenetics of dolutegravir in Africans

Using data from the ADVANCE study the authors developed a

population pharmacokinetic model of dolutegravir and  demonstrated the effect of the UGT1A1 rs887829 genotype on dolutegravir clearance. They estimated clearance of 0.78 L/h for C/C (normal), with a 10.8% and 25.9% decrease in clearance for C/T (heterozygous), and T/T (homozygous), respectively.

The paper was published in the Journal of infectious diseases can be found here.